Lantheus Medical Imaging   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: North Billerica MA United States (1956)
Status: No NME R&D (1956)

Organization Overview

First Clinical Trial
2003
NCT00162344
First Marketed Drug
1974
xenon xe-133
First NDA Approval
1997
samarium-153 lexidronam (quadramet)
Last Known Activity
2019

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

LANTHEUS MEDCL | LANTHEUS MEDICAL | Lantheus Medical Imaging | Medical Monitor - Lantheus Medical Imaging

Active Ingredients

Marketed Drugs (10)

fludeoxyglucose f-18 (2014)

gadofosveset trisodium (ablavar) (2008)

gallium citrate ga 67 (1976)

perflutren protein-type a microspheres (Optison) (2001)

samarium-153 lexidronam (quadramet) (1997 NDA)

technetium-99m bicisate (1994)

technetium tc-99m sestamibi (1990)

thallous chloride ti 201 (1977)

ultra-technekow fm (1976)

xenon xe-133 (1974)

Drugs in Phase 4 Trials (3)

Key: Lantheus Medical Imaging (2) Acquired (1)

methylnaltrexone (relistor) (31 trials)

perflutren protein-type a microspheres (Optison) (13 trials)

technetium tc-99m sestamibi (6 trials)

Drugs in Phase 3 Trials (5)

Key: Lantheus Medical Imaging (3) Acquired (2)

99mtc mip 1404 (6 trials)

dcfpyl (8 trials)

flurpiridaz (2 trials)

Octafluoropropane (1 trial)

technetium tc-99m tetrofosmin kit (1 trial)

Drugs in Phase 2 Trials (17)

Key: Lantheus Medical Imaging (5) Acquired (12)

131i-psma-1095 (1 trial)

90y-smt487 (1 trial)

acetylcysteine (mucomyst) (1 trial)

bms747158 (5 trials)

ctt1057 (1 trial)

enzalutamide (xtandi) (1 trial)

iobenguane (123i) (6 trials)

iobenguane sulfate i-131 (1 trial)

lmi 1195 (2 trials)

losartan (cozaar) (1 trial)

lutetium dotatate lu-177 (Lutathera) (1 trial)

paclitaxel (taxol) (1 trial)

pro-140 monoclonal antibody (3 trials)

pro-542 (1 trial)

prostate specific membrane antigen (5 trials)

retinoic acid (1 trial)

zemiva (1 trial)

Drugs in Phase 1 Trials (9)

Key: Lantheus Medical Imaging (0) Acquired (9)

123i-mip-1072 (3 trials)

123i-mip-1095 (1 trial)

131i-mip-1095 (1 trial)

131i-mip-1145 (1 trial)

99mtc mip 1405 (1 trial)

capromab pendetide (Prostascint) (1 trial)

moxifloxacin (avelox) (1 trial)

naloxone (narcan) (1 trial)

paroxetine (paxil) (1 trial)

Drugs in Other Trials (3)

gadofosveset trisodium (ablavar) (3 trials)

glucagon-like peptide-1 (1 trial)

regadenoson (lexiscan) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 2)

Carcinoma, Renal Cell (Phase 2)

Cardiovascular Diseases (Phase 4)

Coronary Artery Disease (Phase 4)

Coronary Disease (Phase 4)

Coronary Restenosis (Phase 4)

Diabetes Mellitus (Phase 4)

Diabetes Mellitus, Type 2 (Phase 4)

Glioblastoma (Phase 2)

Gliosarcoma (Phase 2)

Heart Diseases (Phase 4)

Heart Failure (Phase 2)

Infarction (Phase 4)

Ischemia (Phase 2)

Kidney Diseases (Phase 2)

Kidney Diseases, Cystic (Phase 2)

Kidney Neoplasms (Phase 2)

Mucocutaneous Lymph Node Syndrome (Phase 3)

Myocardial Infarction (Phase 4)

Myocardial Ischemia (Phase 4)

Pulmonary Heart Disease (Phase 4)

Renal Insufficiency, Chronic (Phase 2)

von Hippel-Lindau Disease (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 104
  • # of Trial APIs: 37